In a recent LinkedIn post, James Cox 287721159 discusses key takeaways from the Veeva Systems R&D and Quality Summit, emphasizing the critical human-tech int…
In a recent LinkedIn post, James Cox shares the results of a poll on leading life sciences hubs, highlighting Boston’s dominance and questioning why major ci…
In a recent LinkedIn post, James Cox explores the challenges organizations face in operationalizing AI, arguing that execution capability and organizational …
In a recent LinkedIn post, James Cox discusses the ongoing challenges and emerging opportunities within the biotech market, particularly for early-stage comp…
In a recent LinkedIn post, James Cox analyzes biotech market data, revealing a significant rebound in later-stage funding and IPOs while early-stage capital,…
In a recent LinkedIn post, James Cox explores career opportunities at BioTalent and BioX, highlighting significant earning potential, a high-performance cult…
In a recent LinkedIn post, James Cox discusses his observations from Swiss Biotech Day 2026, highlighting the event’s record attendance and the growing confi…
In a recent LinkedIn post, James Cox analyzes the European innovation landscape following his attendance at The Pitch event, highlighting the abundance of ta…
James Cox explores the challenges European startups face in converting innovative ideas into capital and execution, as observed at The Pitch event. He highli…
In a recent LinkedIn post, James Cox discusses his participation in a Basel event and his strategic vision for the future of BioTalent, aiming to unite Talen…
